Does Lymphovenous Anastomosis Effect Mammalian Target of Rapamycin Inhibitor-associated Lymphedema Patients?
The mammalian target of rapamycin (mTOR) inhibitors are used to prevent organ transplant rejection and are preferred over other immunosuppressants due to its low nephrotoxicity. However, mTOR inhibitors have been associated with various adverse effects including lymphedema. Although rare in incidenc...
Main Authors: | Inah Yoon, Hyung Bae Kim, Jeongmok Cho, Changsik John Pak, Hyunsuk Peter Suh, Jae Yong Jeon, Joon Pio Hong |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical Publishers, Inc.
|
Series: | Archives of Plastic Surgery |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/a-2201-5881 |
Similar Items
-
Efficacy and patient satisfaction regarding lymphovenous bypass with sleeve-in anastomosis for extremity lymphedema
by: Jae-Ho Chung, et al.
Published: (2019-01-01) -
A clinical study of liposuction followed by lymphovenous anastomosis for treatment of breast cancer-related lymphedema
by: Kun Chang, et al.
Published: (2023-03-01) -
The Quality of Life after Lymphaticovenous Anastomosis in 118 Lower Limb Lymphedema Patients
by: Jin Geun Kwon, et al.
Published: (2023-09-01) -
Effects of Lymphovenous Anastomosis Surgery Using Ultrasonography in Lymphedema From a Pressure Perspective
by: Jayoung Lee, et al.
Published: (2022-08-01) -
Patient-specific surgical options for breast cancer-related lymphedema: technical tips
by: Jin Geun Kwon, et al.
Published: (2021-05-01)